ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The present study aimed to investigate whether DAPK1 methylation occurs in CML patients with or without imatinib resistance, and identified that: i) The DAPK1 promoter was significantly methylated in CML patients (10/43) compared with healthy individuals (0/25); ii) the proportion of imatinib-resistant CML patients demonstrating DAPK1 methylation (6/17) was higher than the proportion of non-resistant CML patients demonstrating DAPK1 methylation (4/26); and iii) the incidence of DAPK1 methylation in resistant patients varied between the different types of BCR-ABL mutation.